StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

Equities researchers at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the stock.

Separately, D. Boral Capital reiterated a “buy” rating and set a $5.00 target price on shares of VolitionRx in a research report on Thursday, March 20th.

VolitionRx Stock Up 4.2 %

NYSE:VNRX opened at $0.55 on Friday. The firm has a market capitalization of $50.97 million, a P/E ratio of -1.53 and a beta of 1.09. The company has a fifty day moving average of $0.59 and a 200-day moving average of $0.64. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.02.

Insider Transactions at VolitionRx

In other VolitionRx news, CEO Cameron John Reynolds acquired 181,818 shares of the stock in a transaction dated Wednesday, March 26th. The stock was purchased at an average cost of $0.55 per share, for a total transaction of $99,999.90. Following the acquisition, the chief executive officer now owns 2,299,222 shares in the company, valued at $1,264,572.10. The trade was a 8.59 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 12.80% of the company’s stock.

Hedge Funds Weigh In On VolitionRx

Several institutional investors and hedge funds have recently made changes to their positions in VNRX. Two Sigma Securities LLC purchased a new stake in VolitionRx during the fourth quarter valued at about $29,000. Millennium Management LLC bought a new stake in shares of VolitionRx in the 4th quarter valued at about $36,000. Northern Trust Corp boosted its holdings in VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after acquiring an additional 28,579 shares during the period. Geode Capital Management LLC grew its position in VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after acquiring an additional 95,900 shares during the last quarter. Finally, Lagoda Investment Management L.P. increased its stake in VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after purchasing an additional 1,481,000 shares during the period. Institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.